Tier 2 — strong

An association of boswellia, betaine and myo-inositol (Eumastós) in the treatment of mammographic breast density: a randomized, double-blind study

V Pasta, G Gullo, A Giuliani, A H Harrath, S H Alwasel, F Tartaglia, A Cucina, M Bizzarri
European review for medical and pharmacological sciences 2015 19(22):4419-4426

Bibliography

PubMed
PMID 26636532
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled trial
ModelHuman participants
Sample76 premenopausal women
InterventionEumastós combination containing Boswellia, betaine and myo-inositol versus placebo
Duration6 months
EndpointsMammographic breast density

What the study showed, in plain terms

Published in 2015, this source examined brain health and combination interventions. Design: Randomized controlled trial. Sample/model: 76 premenopausal women. The exposure or intervention was Eumastós combination containing Boswellia, betaine and myo-inositol versus placebo. Follow-up or treatment period: 6 months.

Breast-density reduction was reported in 60% of the combination group versus 9% of placebo recipients.

Density is a surrogate rather than a cancer outcome. The same-sized companion report may share participants, and betaine's individual effect is unknown.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Breast-density reduction was reported in 60% of the combination group versus 9% of placebo recipients.
  • The recorded outcome domains were Mammographic breast density.
  • The result applies to the tested exposure: Eumastós combination containing Boswellia, betaine and myo-inositol versus placebo; 6 months.

What this study can and cannot tell us

  • Density is a surrogate rather than a cancer outcome. The same-sized companion report may share participants, and betaine's individual effect is unknown.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
A Randomized Pilot Study of Inositol in Association with Betaine and Boswellia in the Management of Mastalgia and Benign Breast Lump in Premenopausal Women
Vittorio Pasta et al. · Breast cancer : basic and clinical research · 2016
Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 2
A study of the treatment of Rett syndrome with folate and betaine
Daniel G Glaze et al. · Journal of child neurology · 2009
Tier 2
A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome
Julia Han et al. · Orphanet journal of rare diseases · 2019
Tier 2
Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression
Francesco Di Pierro et al. · International journal of general medicine · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology